Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide

被引：0
|
作者：
Hortensia Álvarez
Ana Mariño
Nieves Valcarce
Jesús García-González
Helena Díaz-Cambre
Josep M. Llibre
机构：
[1] University Hospital of Ferrol,Infectious Diseases Unit, Internal Medicine Department
[2] University Hospital of Ferrol,Hospital Pharmacy
[3] University Hospital of Ferrol,Psychiatry Department
[4] University Hospital of Ferrol,Nephrology Department
[5] University Hospital Germans Trias i Pujol,Infectious Diseases and “Fight AIDS” Foundation
来源：
Infection | 2019年 / 47卷
关键词：
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Overdose; Suicide attempt;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：115 / 119
页数：4
相关论文
共 50 条
  • [1] Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide
    Alvarez, Hortensia
    Marino, Ana
    Valcarce, Nieves
    Garcia-Gonzalez, Jesus
    Diaz-Cambre, Helena
    Llibre, Josep M.
    [J]. INFECTION, 2019, 47 (01) : 115 - 119
  • [2] Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults
    Bonora, Stefano
    Calcagno, Andrea
    Trentalange, Alice
    Di Perri, Giovanni
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (03) : 409 - 419
  • [3] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
    Greig, Sarah L.
    Deeks, Emma D.
    [J]. DRUGS, 2016, 76 (09) : 957 - 968
  • [4] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
    Sarah L. Greig
    Emma D. Deeks
    [J]. Drugs, 2016, 76 : 957 - 968
  • [5] Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
    Margot, Nicolas
    Cox, Stephanie
    Das, Moupali
    McCallister, Scott
    Miller, Michael D.
    Callebaut, Christian
    [J]. ANTIVIRAL THERAPY, 2017, 22 (05) : 443 - 446
  • [6] Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV
    Imaz, Arkaitz
    Podzamczer, Daniel
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2017, 15 (03) : 195 - 209
  • [7] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight
    Max, Blake
    DeMarais, Patricia
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2021, 32 (01) : 92 - 95
  • [8] Azithromycin/cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamide/ethambutolLack of efficacy
    [J]. Reactions Weekly, 2024, 2009 (1) : 108 - 108
  • [9] Network meta-analysis of darunavir/cobicistat/emtricitabine/tenofovir-alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide in treatment-naive patients with HIV-1 infection
    Van Sanden, S.
    Schweikert, B.
    Moecklinghoff, C.
    Tronczynski, K.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [10] A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
    Huhn, Gregory D.
    Tebas, Pablo
    Gallant, Joel
    Wilkin, Timothy
    Cheng, Andrew
    Yan, Mingjin
    Zhong, Lijie
    Callebaut, Christian
    Custodio, Joseph M.
    Fordyce, Marshall W.
    Das, Moupali
    McCallister, Scott
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 (02) : 193 - 200
12345